HanAll Biopharma

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • USD 10% move → ±KRW 515.4M pre-tax impact, up from ±KRW 364.0M prior year; net USD liability position KRW 5.15B
• • Total borrowings KRW 30.7B newly added vs zero prior year, lifting debt ratio from 26.45% to 39.30%

Business Overview

• • FY2025 consolidated revenue KRW 155.2B, +12% YoY; operating loss KRW 915M vs. operating profit KRW 230M prior year
• • Batoclimab (HL161BKN) Phase 3 MG topline data released Mar 2025, showing superior efficacy vs. competitors; TED Phase 3 topline expected H1 2026

Management Discussion & Analysis

• • Revenue KRW 155.2B (+12% YoY, 6th consecutive record high); operating loss KRW 916M (vs. OP KRW 230M prior year, deficit reversal); net loss KRW 5.6B (vs. net loss KRW 1.8B)
• • 'Biotop' probiotic drug achieved annual sales KRW 23.5B; hair-loss product line exceeded KRW 10B; batoclimab (HL161BKN) milestone revenue KRW 8.1B (+18% YoY) — MG and CIDP trial completion recognized

What are the latest HanAll Biopharma DART filings in 2026?

HanAll Biopharma (KRX code 009420) has filed an annual report on March 18, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did HanAll Biopharma file its most recent annual report?

HanAll Biopharma filed its most recent annual report on March 18, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is HanAll Biopharma's KRX stock code?

HanAll Biopharma's KRX stock code is 009420. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 009420 to look up all HanAll Biopharma disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does HanAll Biopharma file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for HanAll Biopharma.

Where can I find HanAll Biopharma financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from HanAll Biopharma annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.